Studies of Tumor-Penetrating Microparticles for Pancreatic Cancer

Abstract public domain (NIH RePORTER)

The lead investigators at Optimum developed tumor-penetrating microparticles (TPMs), a first-in-class delivery system tailored to the unique anatomical properties of the peritoneal cavity. TPMs are multicomponent, multifunctional, biocompatible, biodegradable, controlled-release polymeric micron-size particles. TPMs are designed to target, penetrate and deliver pharmacodynamically optimized drug levels to the superficial and deep layers of peritoneal tumors. TPMs represent a delivery platform that can be used to deliver small molecule therapeutics, biologics, gene vectors and imaging agents. The first generation TPM, TPM001, is loaded with paclitaxel, with pancreatic cancer as the first indication. The BrIDGs team has completed PK/ADME and IND-directed toxicology studies, and developed and manufactured a clinical grade drug product. The collaborators submitted a successful Investigational New Drug (IND) application to initiate clinical trials, which are ongoing. The BrIDGs team is conducting additional manufacturing work to support the ongoing clinical studies.